Briefs: Morepen Laboratories and Zydus Lifesciences

The company is addressing these observations

Lupin announces completion of pharmacovigilance inspection by USFDA

The inspection included a comprehensive scrutiny of practices and procedures for reporting of adverse events of Lupin’s marketed products worldwide

Lupin announces successful completion of UK MHRA inspection of Pithampur facilities

With the combination of oral solid, inhalation, dermatology, high potent and oral contraceptive products, this is an important facility of the company

Zydus receives final approval from USFDA for Doxepin Hydrochloride Capsules USP, 150 mg

Doxepin Hydrochloride capsule is indicated to treat mental/mood problems such as depression and anxiety

Zydus receives final approval from USFDA for Lubiprostone Capsules, 8 mcg and 24 mcg

Lubiprostone capsule is indicated to treat certain types of constipation (chronic idiopathic constipation and irritable bowel syndrome with constipation)

PM chairs high-level meeting to asses situation of Covid-19 & Influenza

PM emphasises the need to enhance lab surveillance & testing of all Severe Acute Respiratory Illness (SARI) cases & ramp up genome sequencing

PM to address One World TB Summit tomorrow

PM to launch TB-Mukt Panchayat initiative; official pan-India rollout of a shorter TB Preventive Treatment and Family-centric care model for TB

Osteoarthritis candidate MM-II showed durable pain relief in Global Phase 2b study

The data from this study show that MM-II has the potential to provide durable pain relief for our patients

Granules Consumer Health concludes FDA audit with zero observations

The audit is a pre-approval inspection for three products filed from the facility

CTSI appoints Harish Trivedi as CEO, South Asia